Loading stock data…
$20.95+0.20 (+0.99%)
Innoviva, Inc.
Innoviva, Inc. in the Healthcare sector is trading at $20.95 with a market capitalization of $1.5B. Wall Street consensus targets $35.00 (5 analysts), implying a +67.1% move over the next 12 months. The stock is currently 17% below its 52-week high of $25.15, remaining 4.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $119.59M↑ | $97.99M↓ | $114.61M↑ | $107.80M↑ | $100.28M |
| Gross Profit | $90.62M↑ | $82.39M↓ | $101.94M↑ | $75.54M↓ | $83.15M |
| Operating Income | $50.85M↑ | $38.15M↓ | $38.99M↑ | $34.58M↓ | $48.75M |
| Net Income | -$83.42M↓ | $186.59M↑ | $164.15M↑ | $89.91M↑ | $63.69M |
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, an...